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The role of cell adhesion mechanisms is of vital 
significance in very important cell features. Basic 
processes such as embryogenesis, tissue and organ 
pattern formation and tissue architecture are some 
of them. It is believed that changes in cell adhesion 
molecules are implicated in the loss of control of cell 
proliferation and neoplasia. The adhesion molecules 
support and direct the exchange of information bet­
ween two cells; they are not just molecular glue [1]. 
Deregulation and loss of control of cell­cell interactions 
is often associated with the establishment of new in­
teractions and the metastasis process [2, 3]. Various 
classes of cell­cell adhesion molecules are expressed 
in various human tissues and in the skin as well [4]. At 
present, adhesion molecules embrace five categories: 
cadherins, integrins, immunoglobulin gene superfami­
ly members, selectins and CD44.
Cadherins constitute a large superfamily of adhe­
sion molecules. They are transmembraneous gly­
coproteins that connect one cell to another through 
calcium ion­dependent binding [5, 6]. Cadherins are 
important for the intercellular contacts in solid tissues. 
They form the transembrane part of the adherent 
junctions. Among them E­ (epithelial), N­ (neural), 
P­ (placental) and VE­ (vascular endothelial) cadherins 
are the better studied [7, 8]. These adhesive molecules 
consist of five extracellular domains and a conserved 
cytoplasmic region. Intracellularly, cadherins bind to a 
catenin molecule providing a link to the cytoskeleton 
[8]. Each member of the cadherins superfamily has a 
specific binding site allowing binding between cadhe­
rins of the same subtype in a homophilic fashion [9]. 
The complex molecular interactions allow cadherins 
to take part in intercellular communication. They can 
modulate in both normal and malignant tissues all 
functions and differentiation processes. One of those 
functions is the determination of the location of the 
melanocytes in the skin. However, during migration 
melanocyte precursors do not express E­ or P­cadhe­
rin [8]. Inactivation of cadherins leads to disruption 
of the cell­cell adhesion. In contrast, inactivation of 
other adhesion systems, apart from cadherins, has a 
little effect on adhesion [10]. Except of the sensitivity 
of cadherins to act in the absence of calcium ions, 
cadherin function is also disrupted in carcinomas. In 
particular, loss of E­cadherin expression in human 
carcinoma cells is associated with invasiveness and 
dedifferentiation of carcinoma cells [11].
Catenins, which are undercoated cytoplasmic 
proteins, represent very important molecules strongly 
associated with the expression and function of cadher­
ins. Catenins (α­, β­ and γ­) are proteins with a specific 
cytoplasmic domain crucial in cadherin function. They 
link cadherins to the actin filaments network as well 
as to other transmembrane and cytoplasmic proteins 
[1]. The part of the cadherin which links to the actin­
cytoskeleton is the cytoplasmic tail of the cadherin. 
The three members (α­, β­, and γ­catenin) compose 
the catenin family, with α­catenin playing an important 
role in adhesion [12]. Furthermore, the p120 molecule 
is regarded to be a new catenin molecule similar to that 
of γ­catenin. It has been shown that the expression 
of α­ and γ­catenin is reduced or absent in melano­
cytic nevi and melanomas [13]. Altered expression of 
catenins is suggested to be associated with the de­
velopment of the melanocytic lesions. Heterogenous 
expression of catenins in the same lesion strongly 
suggests that catenins may be involved in different 
adhesion mechanisms. No correlation among the 
various types of catenins was shown regarding their 
expression pattern in the same study [13]. It must be 
mentioned that γ­catenin expression is commonly 
reduced in melanomas, in contrast to β­catenin which 
is overexpressed, suggesting a possible indirect role 
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of β­catenin as an oncogene in melanoma cases 
[13]. In the same study, β­catenin was found to be 
expressed by all benign and malignant melanocytic 
lesions [13]. Finally, loss of α­catenin expression was 
directly associated with melanoma progression [13]. 
The most important changes in cadherin and catenin 
expression were observed during the vertical growth 
phase of melanomas. Loss of membranous P­cadhe­
rin and β­catenin expression, minimal membranous 
E­cadherin expression, as well as loss/minor de novo 
membranous N­cadherin expression, represent al­
terations commonly found in melanoma progression 
processes. As a result of these changes mentioned just 
above, cells lose their adhesive capacity and decline 
their resistance to tumorigenetic process [14].
MELANOMA
One of the fastest rising malignancies in the last 
years turns to be cutaneous melanoma [15]. Generally 
melanoma begins with benign nevi and progresses to 
radical and vertical growth [16, 17]. Between those 
phases melanocytic nevus with lentiginous melano­
cytic hyperplasia and aberrant differentiation and/or 
melanocytic dysplasia may occur. Finally, metastases 
may occur after the vertical phase growth [18]. This 
propensity of melanoma to metastasise is the most 
important characteristic that distinguishes it from other 
types of cutaneous malignancies. The appearance of 
melanoma may vary regardless the tumor site. Color 
may also vary from gray or brown to black, red or even 
dark blue [5, 19, 20].
Solid tumors are characterized by loss of cellular 
and morphological features, uncontrolled proliferation, 
invasiveness and colonization of cancer cells to distant 
organs. It is believed that at least in part this is due to 
changes taking place in the microenvironment of nor­
mal cells and alterations in intercellular communication 
between neoplastic and normal cells [21]. Melanocytes 
are located in the basal layer of the epidermis and they 
maintain during life a stable­ratio of 1:5 with basal ke­
ratinocytes [22]. Melanocytes protect keratinocytes 
through synthesis and donation of melanin after the 
effect of ultraviolet light action [10]. In cases of nevis or 
melanomas this balance is not kept and the transforma­
tion disturbs the regulated induction of melanocyte divi­
sion. In normal state, homeostasis, which determines if 
a cell remains quiescent, proliferates, differentiates, or 
undergoes apoptosis, should be maintained [23]. The 
intercellular adhesion of melanocytes with keratino­
cytes is achieved by adherent and regulatory junctions 
via participation of E­cadherin molecules. Cadherins 
without linkage to the actin cytoskeleton may undergo 
weaker interactions. These cells are believed to be more 
prone to cell migration [24]. 
In normal state, the established adhesion bet­
ween melanocytes and keratinocytes controls the 
melanocyte growth and the expression of cell surface 
receptors. The contacts between keratinocytes and 
melanocytes are established with the extension of 
melanocytes’ dendrites that contribute to the estab­
lishment of multiple contacts. When control process 
is lost, then melanoma cells escape and melanoma 
tumorigenesis is started. A shift in the expression of 
E­cadherin, P­cadherin and desmoglein mainly to 
N­cadherin is observed in melanoma cells. As a re­
sult the anchorage to the basement membrane is lost 
and homeostasis mechanisms are dysregulated. The 
dysregulation of the balance of the epidermal melanin 
units triggers a continuous proliferation of melanocytes 
leading, finally, to melanoma development [25, 26]. It 
has been shown that loss of regulatory dominance by 
keratinocytes occurs in concert with downregulation of 
E­cadherin expression in melanomas [27]. Functional 
E­cadherin in melanoma cells is believed to lead to 
cell adhesion to keratinocytes, protecting thus from 
motility, proliferation and invasion [28]. Through the 
complex process of metastasis, tumor cells undergo 
drastic changes in cell shape and a reorganization of 
the actin cytoskeleton is observed [29]. Cells separate 
from the primary tumor mass and migrate through the 
extracellular matrix, survive in the vascular system and 
extravasate into foreign environments forming the me­
tastases sites [30]. In contrast, normal melanocytes 
appear heterotypic gap junctional intercellular com­
munication with keratinocytes [31]. Loss of adhesion to 
their original neighbors is one of the first steps, which 
plays significant role in the invasion of melanoma into 
adjacent tissues as well as in metastasis sites [10].
E-CADHERIN IN MELANOMAS
E­cadherin is a transmembrane glycoprotein locali­
zed in the adherence junctions mediating cell­to­cell 
adhesion through calcium­dependent homotypic 
interactions [32]. E­cadherin is the most important 
molecule in the interactions between melanocytes and 
keratinocytes. Under normal conditions, E­cadherin 
is expressed on the cell surface of keratinocytes and 
melanocytes. If E­cadherin is not expressed, keratino­
cytes cannot interact with the melanocytes, which now 
are not regulated by the first [10]. Apart from the cell­
to­cell interactive role of E­cadherin, it is regarded that 
it also suppresses epithelial tumor invasiveness and 
metastasis [6, 33, 34]. Keratinocyte mediated control, 
such as coordinated proliferation and downregulation 
of metastasis, is restored by forced E­cadherin expres­
sion in melanoma cells [35]. All epidermal layers in hu­
man adult and infant skin, including skin appendages, 
express on their cell surfaces E­cadherin [1]. E­cadhe­
rin distribution on all of the plasma membranes of 
keratinocytes was detected by ultrastructural studies 
[36]. E­cadherin expression was absent on dermal sur­
faces of basal cells [36]. However, dense deposits of 
E­cadherin in the intercellular spaces of desmosomes 
were observed [36]. Furthermore, it is revealed by 
immunohistochemical studies that the normal human 
epidermal melanocytes express E­ and P­cadherin in 
contrast to melanoma cells [37]. This fact was proved 
by the use of melanoma cell lines, which did not react 
with antibodies against human E­ and P­cadherin [37]. 
When E­cadherin is not expressed, melanoma cells 
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escape from the control through keratinocytes. This 
downregulation of E­cadherin is associated with gap 
junction incompatibility to keratinocytes [31].
In general, low levels of E­cadherin may play an 
important role in tumor progression, as occurs in 
many carcinomas since cadherin loss is associated 
with absence of differentiation and a more invasive 
growth pattern [25, 38]. The suppressed E­cadherin 
expression in carcinoma cells showed an increased 
invasive potential in in vitro studies and the deep com­
ponents of occasional melanoma showed substantial 
reductions in cadherin expression [39, 40]. In cases 
of malignant melanomas soluble E­cadherin levels in 
serum were increased. 
One possible explanation of the elevated serum 
E­cadherin levels is that the damaged by invasive tumor 
cells tissue releases E­cadherin. Another explanation is 
that this soluble form may be degraded from E­cadhe­
rin primarily expressed on tumor cells [41, 42]. Loss 
of functional E­cadherin let melanocytes to escape 
from the neighboring keratinocytes. In early melanoma 
stages may still exist a basement membrane part, which 
becomes irregular and dysfunctional [43]. 
Very important role in E­cadherin expression plays 
the Snail protein. Overexpression of the Snail protein 
reduces E­cadherin expression and increases the 
metastatic potential of melanoma cells [44]. Sup­
pression of the Snail protein expression reduces the 
metastatic potential of melanoma cells [45]. Another 
factor that can also lead to E­cadherin and P­cadherin 
downregulation in human epidermal melanocytes, 
is the exposure to UVB­irradiation [46]. Dysfunc­
tion of E­cadherin can be seen as change in cellular 
localization, associated with high invasiveness and 
metastasis of the overlying melanoma cells [47]. It 
has been shown that the expression of membranous 
E­cadherin remains in large amount during malignant 
transformation in the radical growth phase of mela­
noma and metastasis process 14]. Downregulation 
of E­cadherin and/or its dysfunction is regarded to 
be one of the earlier steps in the development of me­
tastases in carcinomas, in general. This event may 
also be one of the first steps in the development of 
metastases in cutaneous melanomas cases [48]. It is 
now well known that Snail leads to repression of the 
cell­cell adhesion molecule of E­cadherin. E­cadherin 
gene is the first gene, which was described to be 
targeted by Snail protein. Snail belongs to the Snail 
superfamily of zinc­finger transcription factors. Snail 
superfamily is important in morphogenesis as well 
[49]. In a recently published study it was reported an 
important correlation between E­cadherin expression 
and the depth of the primary tumor [50]. E­cadherin 
expression is observed in cultured melanocytes and 
nevus cells. E­cadherin is rarely found in early stages 
of the melanocytic tumor and is lost in invasive and 
metastatic melanoma cells in vitro [51]. Downregula­
tion of E­cadherin may also downregulate genes in­
volved in growth and metastasis possibly by affecting 
the β­catenin/wnt signaling pathways [52]. It has also 
been shown that E­cadherin gene is silenced by at 
least two distinct mechanisms­methylation and trans­
repression by the Snail protein [53]. All metastasizing 
melanomas and their corresponding lymph node me­
tastases may express membranous E­cadherin [47]. 
These results contradict the invasion suppressor role 
described for E­cadherin in carcinoma­derived cell 
lines in vitro [54]. Another significant inverse relation 
was detected between E­cadherin expression and 
survival in some types of tumors [38, 55, 56]. Another 
alternative way to observe the E­cadherin function 
and its relation to the melanoma development, is 
that by the re­expression of E­cadherin in E­cadherin 
deficient melanoma cells. Adenoviral gene transfer 
was used and surprisingly, E­cadherin transduction 
inhibited N­cadherin expression in melanoma cells 
[31]. The same was also proved by the use of full length 
E­cadherin cDNA, which was transduced by the use of 
an adenoviral vector to E­cadherin negative melanoma 
cell lines. The result of E­cadherin restoration was re­
duction of tumorigenicity and melanoma cells’ growth 
retardation; thus, melanocytic phenotype was closer to 
normal [35]. In three­dimensional skin reconstructs it 
was clearly shown that E­cadherin in melanoma cells 
triggers also apoptosis [35]. In some experiments it 
was revealed that full length E­cadherin transfection 
downregulates endogenous N­cadherin expression 
[57]. Although in general, there is a direct association 
between decreased levels of E­cadherin expression 
and tumorigenesis, surprisingly in a study an increase 
of E­cadherin in a malignant lesion was found [32]. 
Furthermore, although non statistically significant, in 
another study, it was reported that E­cadherin expres­
sion tended to be preserved in melanoma [58]. In a skin 
reconstruction model, ectopic adenoviral­mediated 
E­cadherin expression suppresses invasive capacity. 
Specifically, inhibits some adhesion receptors such as 
melanocyte cellular adhesion molecule or ανβ3 integrin 
subunit [35]. It is shown that restoration of E­cadherin 
expression leads to growth retardation and inhibition 
of the invasiveness and metastasis in carcinoma cells 
[59]. Several studies have proposed that E­cadherin 
can act as a molecule that suppresses the invasive 
ability [39, 60]. If exogenous E­cadherin cDNA is 
introduced into epithelioid type cells, a partial tumori­
genicity suppression is observed. This suggests that 
E­cadherin can play an inhibiting role against tumor 
growth [1]. Another role, which can play E­cadherin in 
melanocytes apart from its tumor suppressor role, is 
that of the prevention of naevus’ formation, as well as 
melanomas growth and their metastasis [61].
N-CADHERIN IN MELANOMAS
Melanoma cells lose the capability of expressing 
E­cadherin, but express N­cadherin at high levels 
in vitro and in vivo [25, 62]. During the melanoma 
development this change of cadherin subtypes gives 
to melanoma cells the ability of direct interaction with 
other cells that express N­cadherin. Fibroblasts and 
vascular endothelial cells are some of them. As a result 
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tumor cells invasion, migration and tumor­stroma cell 
adhesion are affected. The described communica­
tion between cells expressing N­cadherin is achieved 
through gap junctions [31]. The role of N­cadherin in 
melanoma metastasis is also suggested by the fact 
that N­cadherin promotes migration of melanoma cells 
over dermal fibroblasts [25]. High levels of N­cadherin 
expression by the melanoma cells play role in the in­
teractions with the N­cadherin positive fibroblasts and 
endothelial cells [28]. It is obvious that the upregula­
tion of N­cadherin endows melanoma cells with their 
new adhesive properties [31]. Apart from adhesive 
properties, loss of E­cadherin and gain of N­cadherin 
expression during the melanoma progression provides 
also new communication properties with N­cadherin­
expressing neighboring melanoma cells or dermal 
fibroblasts [63]. It seems that N­cadherin is the basic 
cadherin expressed by the melanoblastic cells lines 
in vitro. Very important is the amount of N­cadherin 
produced, since it is associated with the transformation 
stage. It has been shown with in vivo studies that the 
pattern of expression of cadherins/catenins is dynamic 
and associated not only with the stage but also with 
the location of the cells [61]. It is suggested that the 
switching of E­cadherin to N­cadherin provides the early 
tumor with important motility and survival advantages; 
however, endogenous E­cadherin is not affected by the 
N­cadherin overexpression [64]. The role of N­cadherin 
mediated cell­cell adhesion could be characterized as 
dual. It can be involved in the spreading of endothelial 
process over transmigrated melanoma cells, but also in 
the early event of transmigration due to the heterotypic 
adhesion between endothelial and melanoma cells 
[29]. Thus, N­cadherin plays a very important role in 
the first stages of melanoma development by affecting 
adhesion and communication properties, promoting 
melanoma cells migration on fibroblasts and by the fact 
that forced expression of N­cadherin in melanocytes 
promotes migration in general. In investigated mela­
noma cells lines, migration can be significantly inhibited 
when the interaction between N­cadherin expressing 
cells is blocked [65]. Blocking of N­cadherin synthesis 
and inhibition of β­catenin signaling pathways, lead to 
impairment of transendothelial migration of melanoma 
cells [66].
P-CADHERIN IN MELANOMAS
A relatively few data is known regarding P­cadherin 
expression in malignant melanomas. P­cadherin is 
expressed on cells of the basal layers as well as on 
the outer layers of skin appendage [1]. It is suggested 
that P­cadherin is involved in the proliferating cell 
compartment [67]. P­cadherin expression in malignant 
melanomas is related to tumor proliferation and pro­
gression supporting the hypothesis that P­cadherin, 
as E­cadherin, is involved in invasion or metastasis [1]. 
The expression of P­cadherin in primary melanocytes 
is well documented. More specifically, a truncated 
variant of P­cadherin missing the transmembrane and 
the cytoplasmic region expressed in melanoma cells 
has been found [68]. It is believed, therefore, that 
the soluble variant of P­cadherin blocks interaction 
between cells, leading to migration and metastasis of 
the malignant melanoma [69]. Cytoplasmic expres­
sion of P­cadherin is associated with increasing tumor 
thickness, level of invasion and reduced survival [69]. 
In cultures with P­cadherin negative cell lines, de novo 
expression of P­cadherin led to promotion of cell­cell 
contact and aggregation [70].
VE-CADHERIN IN MELANOMAS
Another protein belonging to the cadherin super­
family is the adhesive protein VE­cadherin (vascular 
endothelial cadherin). VE­cadherin is expressed by 
endothelial cells promoting cell­cell interactions and 
plays some role in angiogenesis and vascular permea­
bility [71, 72]. VE­cadherin is essential for both the 
development and the maintenance of blood vessels 
[73]. Aggressive human cutaneous and uveal mela­
noma tumor cells express exclusively VE­cadherin, 
in contrast to poorly aggressive tumor cells [7]. The 
expression of VE­cadherin by aggressive melanoma 
tumors is explained by their ability to mimic endothelial 
cells and form consequently vasculogenic networks 
[7]. This is possible under certain conditions, whereas 
melanoma cells form tubular structures and patterned 
networks [74]. VE­cadherin disappeared from the 
endothelial contact underneath the melanoma cell. 
Migration begins with the small melanoma cells pene­
trating the VE­cadherin negative regions between 
endothelial cells [29].
DYSADHERIN IN MELANOMAS
Recently it is reported the existence of a cancer­
associated cell membrane glycoprotein named dys­
adherin, with an anti­adhesive role The expression of 
this protein in cutaneous malignant melanoma is as­
sociated with tumor aggressiveness and seems to be 
a marker of poor prognosis [58]. E­cadherin function 
and expression is downregulated by dysadherin. This 
was proved by experiments where cells transfected 
with dysadherin cDNA downregulated E­cadherin, 
and promoted metastasis to the liver in an animal 
model [75]. Dysadherin expression also was studied in 
some malignancies in humans by our research group 
[76–78]. Of course, further studies are needed to elu­
cidate the role of dysadherin in human cancer cases 
and particularly, in malignant melanomas.
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РОЛЬ КАДГЕРИН/КАТЕНИНОВОГО КОМПЛЕКСА ПРИ 
ЗЛОКАЧЕСТВЕННОЙ МЕЛАНОМЕ 
В обзоре обсуждается роль кадгерин/катенинового комплекса при злокачественной меланоме. Кадгерины представляют 
собой суперсемейство адгезивных молекул, среди которых наиболее изучен эпителиальный кадгерин (E­кадгерин), выпол­
няющий ключевую роль в норме и при инвазивном опухолевом росте и метастазировании. В ткани злокачественных меланом 
уровень экспрессии E­кадгерина изменен, его снижение или отсутствие связано с инвазивным ростом и метастазированием 
опухоли. При образовании злокачественных меланом в меланоцитах отмечают замену экспрессии E­кадерина на таковую 
неврального кадгерина (N­кадгерина). Кроме того, коротко обсуждается роль плацентарного кадгерина (P­кадгерина), 
эндотелиального кадгерина сосудов (VE­кадерина) и недавно идентифицированного дисадгерина.
Ключевые слова: молекулы адгезии, кадгерин, катенин, дисадгерин, меланома.
Copyright © Experimental Oncology, 2006
